AI · Policy · 2026-09-09 10:06:00
ARPA-H plans to commit $62.7 million to develop AI bots that direct heart failure treatment. The program, called ADVOCATE, aims to produce partially autonomous FDA-authorized devices that assess symptom severity, prescribe drugs, and order lab tests. The first awards go to Atman Health, UpDoc, Tempus AI, and teams from Stanford, Duke, and Kaiser Permanente. The first-year commitment is $33.7 million. Many of the 6.7 million Americans with heart failure lack access to specialists, and the hope is that these AI agents can address the gap, especially in rural and underserved settings.
Auto-generated summary for reference only. RSS